• Natera (NasdaqGS:NTRA) raised its full-year 2026 revenue and gross margin guidance after reporting record test volumes.
• The company cited accelerating growth in both women's health and oncology segments as key drivers.
• Natera also outlined plans to commercially launch its Signatera MRD test in Japan, aiming to extend its international reach.

Natera enters this update with its stock at $219.82 and a 1 year return of 35.2%, and a 3 year return that is a very large multiple of its earlier level. The shares are down 3.9% year to date but up 6.6% over the past week, which indicates that investors have recently reacted positively to new information. In this context, the higher 2026 guidance and segment momentum provide additional insight into how the company is positioning itself in women's health and oncology testing.

For long term oriented investors, the planned Signatera MRD launch in Japan is a key development to watch, because it directly relates to Natera's efforts to build a broader international business. As you assess NasdaqGS:NTRA, the focus is likely to be on how effectively the company translates this guidance update and new market entry into sustained test volumes and margins over time.

Stay updated on the most important news stories for Natera by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Natera.

Natera’s guidance raise rests on tangible Q1 data: revenue of US$696.64 million, up 38.8% year on year, and more than 1 million tests processed in a single quarter. That points to strong demand in both women’s health and oncology, where products like Signatera for minimal residual disease testing are gaining traction against peers such as Guardant Health and Exact Sciences. The higher 2026 revenue and gross margin ranges anchor this update in management’s current visibility on volumes, pricing and product mix, rather than just sentiment. At the same time, Natera still reported a net loss of US$85.09 million in Q1, with loss per share widening to US$0.60, so the guidance shift sits alongside ongoing investment in clinical trials, commercial rollout and R&D. The planned Signatera launch in Japan adds another layer, opening access to a large oncology market but also bringing regulatory, reimbursement and go-to-market execution questions. For you as an investor, the key question is whether test-volume momentum and pricing can outpace these costs enough to support the higher gross margin outlook while the company continues to scale internationally.

How This Fits Into The Natera Narrative

• The guidance increase and record test volumes align with the narrative that growing adoption of molecular diagnostics across oncology and women’s health can support higher revenue and gross margins over time.
• The wider quarterly net loss reminds you that heavy R&D and SG&A spend, highlighted as a key risk in the narrative, is still a live issue that could delay the path to sustained profitability if revenue growth slows.
• The planned Japan launch for Signatera extends the story into a new geography, and this specific international expansion focus is not fully captured in the largely US centric revenue and trial examples in the narrative.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Natera to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Natera continues to post sizeable losses, with a Q1 2026 net loss of US$85.09 million and loss per share of US$0.60, so the timing and durability of any move to consistent profitability remains uncertain.
• ⚠️ Expanding Signatera into Japan brings regulatory, reimbursement and competitive risks in a market where global diagnostics companies and local players may already be entrenched.
• 🎁 Q1 revenue of US$696.64 million, 38.8% higher than a year earlier, and over 1,013,600 tests processed support the reward case that demand for Natera’s molecular tests is scaling.
• 🎁 The higher 2026 revenue guidance of US$2.74b to US$2.82b and gross margin outlook of 64% to 66% signal management confidence that volume, pricing and product mix can support stronger unit economics.

What To Watch Going Forward

After this update, it is worth tracking whether Natera continues to hit or exceed its raised revenue and gross margin ranges, especially as oncology test volumes expand and women’s health products such as Fetal Focus mature. Pay attention to how quickly Signatera gains traction in Japan once launched, including any disclosures on pricing, reimbursement arrangements and physician uptake. The trend in operating losses and cash inflow will also matter, given the higher spending on clinical trials, acquisitions such as Foresight Diagnostics, and international expansion. Any shifts in competitor behavior from companies like Guardant Health and Exact Sciences, or reimbursement changes that affect molecular residual disease and non invasive prenatal testing, could influence how durable this growth and margin profile turns out to be.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Natera, head to the community page for Natera to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.